Pharmaceutical grade cannabis and hemp products provider Creso Pharma has entered into a commercial agreement with health and wellness market solutions provider DHS Business International (DHS).
This agreement is related to the distribution of Creso Pharma’s cannabidiol (CBD) products to retailers and consumers in the Brazilian retail market.
Go deeper with GlobalData
It also includes the Swiss-made CannaQIX product range manufactured by Good manufacturing practices (GMP) certified facilities.
The companies are aiming to cover 60% of the retail network in three major areas in Brazil – Sao Paulo, Rio de Janeiro and Parana.
The expansion will enable Creso to operate over 4,200 points of sale across the three markets.
Creso Pharma CEO and co-founder Dr Miri Halperin Wernli said: “Signing an agreement with DHS so quickly after the ANVISA policy change highlights Creso’s quick thinking and ability to capture opportunity on an international scale.
“DHS has extensive experience and strong partnerships throughout Brazil and Latin America more broadly. These markets have very large populations and provide a large opportunity for the company in the coming months.
“We look forward to working with DHS to ensure our products are brought to market as quickly as possible. The company will provide ongoing updates to shareholders as developments progress.”
Creso already has operations in the country in partnership with SIN Solution and SR Group.
Products are expected to be made available through retailers by the fourth quarter of this year.
